Palvella Therapeutics, Inc.
PVLA
$120.57
-$5.22-4.15%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -49.30M | -41.72M | -32.95M | -28.38M | -23.08M |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 15.87M | 12.89M | 11.02M | 9.50M | 8.16M |
| Change in Net Operating Assets | 4.33M | 3.82M | -3.54M | -1.45M | -1.59M |
| Cash from Operations | -29.10M | -25.01M | -25.47M | -20.34M | -16.51M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -55.44M | -- | -- | -- | -- |
| Cash from Investing | -55.44M | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | 6.00M | 8.43M | 18.43M |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 231.65M | 763.00K | 60.66M | 60.42M | 60.07M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -16.38M | -1.42M | 7.52M | 7.49M | 7.39M |
| Cash from Financing | 215.27M | -660.00K | 74.17M | 76.34M | 85.89M |
| Foreign Exchange rate Adjustments | 37.00K | 46.00K | 659.00K | -111.00K | -3.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 130.77M | -25.62M | 49.36M | 55.90M | 69.38M |